AB0148 COULD THE RENIN-ANGIOTENSIN SYSTEM AFFECT THE PROGNOSIS OF GIANT CELL ARTERITIS? SINGLE-CENTRE RETROSPECTIVE OBSERVATIONAL STUDY

Background

About half of patients with giant cell arteritis (GCA) relapse while tapering glucocorticoid therapy1. A previous observational study reported that blockade of the renin-angiotensin system, with angiotensin II receptor blockers (ARBs), was associated with lower relapse risk2.

Objectives

To determine whether angiotensin blockade, with angiotensin converting enzyme inhibitor (ACEi) or ARB, is associated with differential relapse risk in GCA.

Methods

GCA patients from a tertiary centre diagnosed 2012–2020 with two years follow-up were identified from UK GCA Consortium. All provided written informed consent. Retrospective review of medical records included demographics, comorbidities, drug history, inflammatory markers and relapses. Relapse was defined as return of symptoms, raised inflammatory markers, or active vasculitis on imaging confirmed by the treating clinician. Relapse-free survival was analysed using Kaplan Meier (KM) curves and Cox proportional hazards.

Results

111 patients were included (Table 1: demographic data), all were initially treated with 40–60mg Prednisolone. 42% received further immunosuppressants due to relapse or disease severity. 50% patients relapsed in two years, presenting with cranial symptoms (72%), PMR-like symptoms (30%) and/or raised inflammatory markers (48%). There was no association between relapse and age, gender, comorbid HTN/IHD or pre-steroid inflammatory markers and relapse. Rate of steroid taper can affect relapse. EULAR recommend 15–20mg of steroid by three months3. 9 patients relapsed within that time and were excluded, there was no difference in steriod dose at three months between the two groups. KM analysis showed ACEi did not significantly affect time to relapse compared to no angiotensin blockade (HR 0.57, 95% CI 0.28 – 1.18, unadjusted p-value=0.128), and neither did an ARB (HR 0.78, 95% CI 0.31 – 1.98, unadjusted p-value=0.605).

Table 1.

demographic data at baseline.

Relapse (n = 56)No Relapse (n = 55)Patient FactorsAge median (IQR)70 (65-74)73 (67-78)Male Sex n (%)16 (29)20 (36.36)Medications n (%)ACEi9 (15)16 (29)ARB7 (12)7 (13)Comorbidities n (%)CKD4 (7)9 (16)IHD6 (11)5 (9)Prediabetes11 (20)10 (18)DM1 (2)5 (9)HTN22 (40)23 (42)Current Smoker6 (10)2 (4)GCA Factors median (IQR)CRP pre-treatment69 (32 – 131)64 (23 -115)ESR pre-treatment50 (37 -95)4 (22 -72)Steroid dose at 3 months19 (15 -20)15 (10-20)Figure 1.

Unadjusted KM survival curve showing probability of relapse in patients 1) taking ACEi, 2) taking ARB, 3) taking neither ACEi or ARB, 4) with no comorbid HTN or IHD at diagnosis, and 5) experienced comorbid HTN/IHD. There was no significant difference in relapse free survival in patients on an ACEi compared to those taking neither ACEi or ARB.

Conclusion

In the two years following GCA diagnosis 50% relapsed. There was no significant difference in the rate of relapse in patients taking an ACEi or ARB. The main limitation, in this retrospective, observational study was the inability to exclude a reluctance of clinicians to diagnose GCA relapse in the presence of cardiovascular comorbidity. A randomised controlled trial would be needed to determine whether starting an ACEi could reduce relapse risk in patients with new-onset GCA.

References

[1]Mainbourg, S. et al. Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis. Arthritis Care Res.72, 838–849 (2020).

[2]Alba, M. A. et al. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. Semin. Arthritis Rheum.43, 772–777 (2014).

[3]Hellmich, B. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis79, 19–30 (2020).

Disclosure of Interests

Ranjana Venkateswaran: None declared, Karan Gour: None declared, Louise Sorensen: None declared, Charlotte Harden: None declared, Sizheng Steven Zhao: None declared, Ann Morgan Speakers bureau: Roche/Chugai., Consultant of: GSK, Roche, Chugai, AstraZeneca, Regeneron, Sanofi, Vifor., Grant/research support from: Roche, Kiniksa Pharmaceuticals, Sarah Mackie Consultant of: Roche/Chugai, AbbVie, AstraZeneca, Sanofi, Pfizer., Grant/research support from: Attendance at ACR21 supported by Pfizer. Attendance at EULAR2019 supported by Roche.

Utility of video-EEG monitoring in a tertiary care epilepsy center

Our video-EEG monitoring (VEEG) unit is part of a typical metropolitan tertiary care center that services a diverse patient population. We aimed to determine if the specific clinical reason for inpatient VEEG was actually resolved. Our method was to retrospectively determine the stated goal of inpatient VEEG and to analyze the outcome of one hundred consecutive adult patients admitted for VEEG. The reason for admission fit into one of four categories: 1) to characterize paroxysmal events as either epileptic or nonepileptic, 2) to localize epileptic foci, 3) to characterize the epilepsy syndrome, and 4) to attempt safe antiepileptic drug adjustment. We found that VEEG was successful in accomplishing the goal of admission in 77% of cases. The remaining 23% failed primarily due to lack of typical events during monitoring. Furthermore, of the overall study cohort, VEEG outcomes altered medical management in 53% and surgery was pursued in 5%.

What constitutes high quality of care for adults with epilepsy?

BACKGROUND

Providers are increasingly being held accountable for the quality of care provided. While quality indicators have been used to benchmark the quality of care for a number of other disease states, no such measures are available for evaluating the quality of care provided to adults with epilepsy. In order to assess and improve quality of care, it is critical to develop valid quality indicators. Our objective is to describe the development of quality indicators for evaluating care of adults with epilepsy. As most care is provided in primary and general neurology care, we focused our assessment of quality on care within primary care and general neurology clinics.

METHODS

We reviewed existing national clinical guidelines and systematic reviews of the literature to develop an initial list of quality indicators; supplemented the list with indicators derived from patient focus groups; and convened a 10-member expert panel to rate the appropriateness, reliability, and necessity of each quality indicator.

RESULTS

From the original 37 evidence-based and 10 patient-based quality indicators, the panel identified 24 evidence-based and 5 patient-based indicators as appropriate indicators of quality. Of these, the panel identified 9 that were not necessary for high quality care.

CONCLUSION

There is, at best, a poor understanding of the quality of care provided for adults with epilepsy. These indicators, developed based on published evidence, expert opinion, and patient perceptions, provide a basis to assess and improve the quality of care for this population.

Safety profile of levetiracetam

Levetiracetam was approved in November 1999 as add-on therapy for the treatment of partial-onset seizures in adults (age 16 years and older). This review focuses on recently published data from four well-controlled studies in patients with partial-onset seizures with or without secondary generalization. When levetiracetam was given along with other antiepileptic drugs (AEDs), the most frequently reported adverse events were central nervous system related. Adverse events were usually mild to moderate in intensity, with the most frequently reported events occurring predominantly during the first 4 weeks of treatment. No relationship was apparent between the dose of levetiracetam and the most commonly reported adverse events in well-controlled clinical trials within the recommended dose range of 1,000-3,000 mg/day. Levetiracetam is a Pregnancy Category C drug. Overall, when used in combination with other AEDs, levetiracetam was generally well tolerated as add-on treatment for partial-onset seizures.

Epileptogenesis: left or right hemisphere dominance? Preliminary findings in a hospital-based population

The aim of this study was to determine if there is cerebral cortical hemispheral asymmetry in human epileptogenesis. We studied 75 epilepsy patients using electroencephalograms, neuroimaging, ictal semiology and physical examination to determine if epilepsy originates more frequently from the left or the right hemisphere. We considered epilepsy to be definitely-lateralized if one or more of these was abnormal unilaterally and there were no contradictory findings. Twenty-seven of the patients had lateralized epilepsy: 20 from the left hemisphere and seven from the right hemisphere (P< 0.05). These findings from our hospital-based ambulatory patient population suggest that the left hemisphere is more epileptogenic than the right. Further study of lateralization of epileptogenesis in a community population-based sample of incident new-onset cases seems warranted.

Genome scan of idiopathic generalized epilepsy: evidence for major susceptibility gene and modifying genes influencing the seizure type

Idiopathic generalized epilepsy (IGE) is a common, complex disease with an almost exclusively genetic etiology but with variable phenotypes. Clinically, IGE can be divided into different syndromes. Varying lines of evidence point to the involvement of several interacting genes in the etiology of IGE. We performed a genome scan in 91 families ascertained through a proband with adolescent-onset IGE. The IGEs included juvenile myoclonic epilepsy (JME), juvenile absence epilepsy (JAE), and epilepsy with generalized tonic clonic seizures (EGTCS). Our linkage results support an oligogenic model for IGE, with strong evidence for a locus common to most IGEs on chromosome 18 (lod score 4.4/5.2 multipoint/two-point) and other loci that may influence specific seizure phenotypes for different IGEs: a previously identified locus on chromosome 6 for JME (lod score 2.5/4.2), a locus on chromosome 8 influencing non-JME forms of IGE (lod score 3.8/2.5), and, more tentatively, two newly discovered loci for absence seizures on chromosome 5 (lod scores 3.8/2.8 and 3.4/1.9). Our data also suggest that the genetic classification of different forms of IGE is likely to cut across the clinical classification of these subforms of IGE. We hypothesize that interactions of different combinations of these loci produce the related heterogeneous phenotypes seen in IGE families.

Vagus nerve stimulation treatment for Lennox-Gastaut syndrome

Lennox-Gastaut syndrome is a severe age-specific epilepsy syndrome that presents with medication-resistant seizures in childhood. Antiepileptic drugs are the mainstay of treatment. Nonpharmacologic treatments include corpus callosum section and the ketogenic diet. However, no single treatment is safe and effective. We treated 13 patients with Lennox-Gastaut syndrome between the ages of 4 and 44 years (mean, 16.7 years) with vagus nerve stimulation. During the first 6 months of treatment, vagus nerve stimulation produced a median seizure rate reduction of 52% (range, 0% to 93%; P = .04). At 6 months of follow-up, three patients had a greater than 90% reduction in seizures, two had a greater than 75% reduction, one had a greater than 50% reduction, and six had at least a 25% reduction. One patient did not improve. No patient worsened after initial improvement. Side effects, including hoarseness, coughing, and pain in the throat, were transient and tolerable. No patient discontinued vagus nerve stimulation. Our results suggest that vagus nerve stimulation could be an effective and safe adjunct therapy for the treatment of Lennox-Gastaut syndrome.

No evidence for a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q

Juvenile myoclonic epilepsy (JME) is a distinct epileptic syndrome with a complex mode of inheritance. Several studies found evidence for a locus involved in JME on chromosome 6 near the HLA region. Recently, Elmslie et al. [1997] reported evidence of linkage in JME to chromosome 15q14 assuming a recessive mode of inheritance with 50% penetrance and 65% linked families. The area on chromosome 15q14 encompasses the location of the gene for the alpha-7 subunit of the nicotinic acetylcholine receptor. This could fit the hypothesis that there are two interacting loci, one on chromosome 6 and on chromosome 15 or that there is genetic heterogeneity in JME. In an independent dataset of JME families, we tested for linkage to chromosome 15 but found little evidence for linkage. Moreover, families with more than one family member affected with JME provide a lodscore of 3.4 for the HLA-DR/DQ haplotype on chromosome 6. The lodscore for these same families on chromosome 15q14 is <-2 assuming homogeneity and the maximum lodscore is 0.2 assuming alpha =.25. Only one of these families has a negative lodscore on chromosome 6 and a positive lodscore of 0.5 on chromosome 15q14. Our results indicate that this possible gene on chromosome 15 plays at most a minor role in our JME families. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:49-52, 2000.

Reproducibility and complications in gene searches: linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy

Evidence for genetic influences in epilepsy is strong, but reports identifying specific chromosomal origins of those influences conflict. One early study reported that human leukocyte antigen (HLA) markers were genetically linked to juvenile myoclonic epilepsy (JME); this was confirmed in a later study. Other reports did not find linkage to HLA markers. One found evidence of linkage to markers on chromosome 15, another to markers on chromosome 6, centromeric to HLA. We identified families through a patient with JME and genotyped markers throughout chromosome 6. Linkage analysis assuming equal male-female recombination probabilities showed evidence for linkage (LOD score 2.5), but at a high recombination fraction (theta), suggesting heterogeneity. When linkage analysis was redone to allow independent male-female thetas, the LOD score was significantly higher (4.2) at a male-female theta of.5,.01. Although the overall pattern of LOD scores with respect to male-female theta could not be explained solely by heterogeneity, the presence of heterogeneity and predominantly maternal inheritance of JME might explain it. By analyzing loci between HLA-DP and HLA-DR and stratifying the families on the basis of evidence for or against linkage, we were able to show evidence of heterogeneity within JME and to propose a marker associated with the linked form. These data also suggest that JME may be predominantly maternally inherited and that the HLA-linked form is more likely to occur in families of European origin.

Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group

PURPOSE

Valproate (VPA) triples the half-life of lamotrigine (LTG), and combined use may be difficult. The adverse effect (AE) profile of this combination needs clarification.

METHODS

We prospectively recorded our experience in adding LTG to VPA-containing regimens in 108 patients. Data collected included medications, seizure types and syndromes, and AEs. Patients were followed up to 27 months, until a stable dose was reached, or until LTG was discontinued. Patient management was not altered by this study. There were 60 patients with partial-onset seizures, 30 with generalized onset, and 12 with the Lennox-Gastaut syndrome. In 37, LTG was added to VPA monotherapy, and in 71, to VPA and other drugs. The median starting dose of LTG in our adult patients was 20.8 mg/day.

RESULTS

LTG was added successfully in 86 (80%) patients. It was discontinued in 22 (20%): seven because of rash, seven for other AEs, and nine for other reasons. Rash occurred in 14 (13%) but caused discontinuation of LTG in only seven. We found a rash rate of 14.2% and a discontinuation rate because of rash of 8.7% among 310 patients in whom LTG was added to drug regimens not including VPA. Other AEs included fatigue (12%), gastrointestinal (GI) symptoms (9%), dizziness, headache, and insomnia (3% each). Serious AEs were hallucinations (two patients), hepatic enzyme elevations (two patients), irritability (one patient), and low white blood cell count (one patient). Whether LTG was added to VPA monotherapy or polytherapy made no difference in overall AE rate.

CONCLUSIONS

LTG can be added to VPA with an acceptable incidence of side effects. LTG-induced rashes are no more common with VPA than with other drugs when LTG is added at very low initial dosages. Rashes are potentially serious and should be evaluated promptly.

Evidence for linkage of adolescent-onset idiopathic generalized epilepsies to chromosome 8-and genetic heterogeneity

Several loci and candidate genes for epilepsies or epileptic syndromes map or have been suggested to map to chromosome 8. We investigated families with adolescent-onset idiopathic generalized epilepsy (IGE), for linkage to markers spanning chromosome 8. The IGEs that we studied included juvenile myoclonic epilepsy (JME), epilepsy with only generalized tonic-clonic seizures occurring either randomly during the day (random grand mal) or on awakening (awakening grand mal), and juvenile absence epilepsy (JAE). We looked for a gene common to all these IGEs, but we also investigated linkage to specific subforms of IGE. We found evidence for linkage to chromosome 8 in adolescent-onset IGE families in which JME was not present. The maximum multipoint LOD score was 3.24 when family members with IGE or generalized spike-and-waves (SW) were considered affected. The LOD score remained very similar (3.18) when clinically normal family members with SW were not considered to be affected. Families with either pure grand mal epilepsy or absence epilepsy contributed equally to the positive LOD score. The area where the LOD score reaches the maximum encompasses the location of the gene for the beta3-subunit of the nicotinic acetylcholine receptor (CHRNB3), thus making this gene a possible candidate for these specific forms of adolescent-onset IGE. The data excluded linkage of JME to this region. These results indicate genetic heterogeneity within IGE and provide no evidence, on chromosome 8, for a gene common to all IGEs.

Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83

This study evaluated gabapentin monotherapy in 275 patients with medically refractory complex partial or secondarily generalized seizures who were taking one or two antiepileptic drugs (AEDs). Following an 8-week baseline, patients received randomized dosages of gabapentin (600, 1,200, or 2,400 mg/d) during a 26-week double-blind phase comprising 2 weeks gabapentin add-on therapy, an 8-week AED taper, and a 16-week gabapentin monotherapy period. Patients exited the study if they experienced a protocol-defined exit event. Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups. Possible reasons for this lack of a dose-response relationship include withdrawal seizures and the limited range of gabapentin dosages studied. Overall, 20% of patients completed the study. Completion rates were higher among patients who had discontinued one AED (23%) than two AEDs (14%), and higher among patients who were not withdrawn from carbamazepine (27%) than among those who were (16%).

Sensitivity to jerky gene dosage underlies epileptic seizures in mice

Animals with one deleted jerky allele are more susceptible to chemically induced seizures than wild-type mice and display recurrent behavioral seizures. The phenotype of these hemizygotes is characterized by no apparent neurological symptoms other than recurrent seizures reminiscent of human idiopathic epilepsy. The jerky gene encodes a 60 kDa protein resembling a number of DNA-binding proteins. Here, we show that the jerky gene is expressed in all tissues examined, including brain, liver, lung, spleen, testis, and ovary, and study an apparent paradox of how an allelic deletion of the ubiquitously expressed jerky gene can lead to hyperexcitability and seizures but not to other symptoms. We demonstrate that jerky has a dosage-sensitive function (haploinsufficiency) in brain and that this sensitivity to reduced jerky dosage could explain the occurrence of seizures in hemizygotes. However, jerky has a nondosage-sensitive function as well, because the total absence of jerky in homozygotes results in abnormalities of somatic and sexual development. A number of idiopathic epilepsies are dominantly inherited, such as benign familial neonatal convulsions, juvenile myoclonic epilepsy, as well as benign epilepsy with centrotemporal spikes, and the pathomechanism of these epilepsies may be based on haploinsufficiency in the brain.

Effect of topiramate on attention

Impaired attention is a frequently reported side effect of anti-epileptic medication, as well as a frequent general complaint of epilepsy. It is thus important to evaluate the effect of new medications on attention processes. Attention was assessed weekly in ten subjects receiving topiramate over a 3 month period. Attention was evaluated with digit span, a widely used index of attention. Different number sequences were constructed and randomized to allow for repeated use. Four of nine subjects showed significant correlations between topiramate dosage and forward digit span measured weekly, such that higher dosage was associated with poorer attention. The average topiramate dosage and seizure reduction did not differ between these subjects and those who did not show a significant relationship.

Left hemispheric dominance of epileptiform discharges

PURPOSE

We reviewed 1,360 EEG reports for all patients studied in two different neurophysiology laboratories during 1 calendar year to determine whether epileptiform discharges have a hemispheric dominance.

METHODS

Both inpatients and outpatients, with or without epilepsy, were included.

RESULTS

Ninety-four records (6.9%) demonstrated generalized epileptiform activity. Of 95 EEG reports indicating spikes solely from one hemisphere, spikes arose from the left in 61 and from the right in 34. Among 50 other records with bilateral independent spikes with lateralization, 40 were left hemisphere dominant and 10 were right hemisphere dominant.

CONCLUSIONS

These findings raise the possibility that the left cerebral hemisphere may generate focal epilepsy more frequently than the right.

Perceived length across the physiological blind spot

Objects falling across the physiological blind spot appear "complete" despite the absence of photoreceptors. Completion of objects may occur across the blind spot because (1) the blind spot is filled in with the background (the associative explanation); (2) the opposite sides of the blind spot may be contiguously represented in the cortex (i.e. the blind spot is simply sewn up-the retinotopic explanation); or (3) the blind spot may be sewn up, with compensatory expansion occurring around the blind spot (the compensation explanation). These theories would predict no size distortions regardless of object size; constant size distortions regardless of object size; and distortions that depend on the size of the object, respectively. To evaluate these explanations, we measured size distortions at the blind spot. We measured length distortions at the blind spot using a criterion-free two-alternative forced-choice method with feedback. Observers compared the lengths of test bars presented across the blind spot with lengths of reference bars presented at the corresponding location in the fellow eye. Test bar lengths ranged from 7-14 deg. Reference bar lengths were in the range of +/- 3 deg of test bar length. From the observers' responses the perceived length of each bar at the blind spot was estimated. Estimates of the precision of length discrimination at the blind spot were also obtained. Our results were consistent with the associative explanation. In all seven observers, length distortions at the blind spot were smaller than 1 deg (< 20% of the vertical height of the blind spot) for all bar lengths tested. For bars that were presented across the blind spot, the precision with which observers could discriminate length was comparable to that of normal periphery (Weber fraction approximately 20%). Both the veridicality and precision of perceived length are preserved around the blind spot.